semaglutide fda approval Clears For Cardiac Risk Reduction in Diabetic Patients A big win for Wegovy:

Some patients prefer this as a way to stay accountable, while others may feel ready to stop altogether

These comments are from skool.com groups (free)

Semaglutide selectively activates the GLP-1 receptor, producing: Glucose-dependent insulin secretion : Reduces hypoglycemia risk compared to non-incretin agents Glucagon suppression : Reduces hepatic glucose output in the hyperglycemic state Gastric emptying delay : Contributes to postprandial glucose control and satiety Central appetite regulation : Acts on GLP-1 receptors in the hypothalamus and brainstem to reduce hunger and alter food preferences The simplicity of semaglutide's single-receptor mechanism is both a limitation (no energy expenditure enhancement from glucagon) and a strength (thoroughly understood pharmacology, predictable effects, extensive safety characterization)

Mielke, L

This blue copper peptide can effectively promote the production of collagen and elastin proteins, increase vascular growth and antioxidant capacity, and stimulate the production of glucose polyamines (GAGs), helping the skin restore its innate ability for self repair

Two health issues that fit this type of description are hip and knee replacements